GC Pharma is working on developing DM combination drugs

Clinical trial approval for combination of Candesartan-Dapagliflozin

GC Pharma is busy building a lineup of ARB-based hypertension drugs called Candesartan.

 

If Atacand, which is Candesartan's original product, has been sold for a long time, it can be seen as a measure to actively utilize its distribution network.

 

It is currently pushing for development of other complexes in addition to single and two complexes.

 

The MFDS approved a Phase I clinical trial plan for the test drug "GC2121" submitted by GC Pharma on the 8th.

 

This clinical trial will be conducted to evaluate safety, pharmacokinetic and drug interactions when administered Candesartan 32 mg/Dapagliflozin 10 mg to healthy adult volunteers.

 

It is interpreted as an early clinical trial to verify the combined effectiveness of Candesartan and Dapagliflozin, or the effectiveness of the compound.

 

Candesartan is an ARB hypertension drug, Atacand by AZ is the original.

 

Dapagliflozin is an SGLT-2 inhibitory diabetes treatment, Forxiga by AstraZeneca is the original.

 

GC Pharma is related to Atacand.

 

This is because it was co-selling with AstraZeneca Korea from 2011 to 2019.

 

Atacand's annual performance was about ₩20 billion.

 

Last year, Atacand also recorded ₩26 billion in outpatient prescriptions based on UBIST.

 

GC Pharma, which had been relatively sluggish in the oral chronic disease treatment market, was evaluated to have competitive distribution while possessing the original Atacand.

 

Since then, GC Pharma has introduced a combination of Candesartan.

 

Rotacand (Candesartan Cilexetil-Rosuvastatin Calcium) was licensed in 2017, and Candesartan Cilexetil-Amlodipine Besylate was licensed last year.

 

Rotacand is a hypertension drug including Candesartan Cilexetil and a hyperlipidemia drug.

 

It is used in patients who administer Rosuvastatin at the same time.

 

Candedipine is also used by Candesartan Cilexetil or Amlodipine Besylate monotherapy in essential hyperthesis, where blood pressure is not properly controlled.

 

Last year, Rotacand posted a record of ₩4.4 billion by UBIST.

 

"Neo Cande," a single product that replaces Candedipine and Atacand, has been on sale since last year, with monthly earnings steadily increasing.

 

Currently, GC Pharma has four single and complex products containing Candesartan.

 

High blood pressure-diabetes complexes are likely to create a new market because they are not commercialized compared to high blood pressure-hyperlipidemia complexes that have already formed a large market.

 

However, it is pointed out that since it is not easy to research and develop a combination of the two diseases, the commercialization process should be watched for now.